The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...

The oral, non-steroidal mineralocorticoid receptor (MR) antagonist has been approved as Kerendia in the US – its first world market – to reduce the risk of kidney function decline, kidney ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

These include hypertension, hypokalemia and edema and are easily manageable with a selective mineralocorticoid antagonist, such as eplerenone, or low-dose corticosteroids. Currently, abiraterone ...

Kerendia (finerenone) – a non-steroidal, selective mineralocorticoid receptor (MR) antagonist – has been shown to reduce the risk of kidney disease progression or renal death by 18% when added ...

Spironolactone is a mineralocorticoid receptor antagonist medication that blocks certain hormones. The study was a randomized, double-blind, placebo-controlled clinical trial (meaning participants ...